company? Let’s change
that.
At Inato, we’re on a mission to accelerate the pace of medical innovation by bringing clinical research to each and every patient, regardless of who they are and where they live. Our platform, made to connect community-based research centers to trials across the globe, aims to create greater visibility, access, and engagement across a more diverse population of doctors and their patients.
Protalix (NYSE, TASE: PLX) is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to gain FDA approval of a protein produced through plant cell-based in suspension expression system. Protalix's unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.
The Public Health Company (PHC Global) is developing the first global biosecurity platform to provide enterprises a SaaS-enabled service for the management of bio-risks. PHC combines world-class expertise with cutting edge technology to be the global solution to enterprise risk management. PHC focuses on intersecting physical world threats across diverse use-cases to deliver actionable and predictive intelligence that enables dynamic risk management with unprecedented speed and scale
Pardes is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines. By capitalizing on emerging patient-friendly innovations from telehealth to new at-home diagnostic tools, Pardes is cultivating and harvesting the fruits of systemic change. We are on a mission to stop a pandemic and start a movement so patients everywhere can get well sooner.
Parachute is a new kind of plasma donation company that allows individuals to earn money while creating life-saving medicine. Plasma is used to create medicine that treats chronic illnesses, including immune disorders, liver disease, bleeding disorders, and cancer. Right now, there’s a severe plasma shortage, which is impacting patients’ access to these life-saving treatments
Systemic Bio is a 3D Systems company based in Houston, Texas, focused on the development of vascularized organ models made out of hydrogels and human cells to be used for drug discovery and development.
Third Harmonic Bio is a clinical-stage biopharmaceutical company developing a highly selective, oral KIT inhibitor for treatment of dermal, respiratory and gastrointestinal inflammatory diseases. KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body’s interfaces with the external environment and that act as the key mediator of the inflammation associated with mast-cell mediated inflammatory diseases. By inhibiting KIT, we believe we can provide broad symptomatic relief to patients with a range of disorders, including chronic spontaneous urticaria and severe asthma
Vow is a cultured meat company, founded and operated in Sydney, Australia. We’re a multidisciplinary team of scientists, technologists and designers, all working together to make sustainable food both irresistible and available to billions of people.
Normunity, Inc., is a biotechnology company creating a new class of precision immuno-oncology medicines, called immune normalizers, that target novel mechanisms that free the body’s normal immunity against cancer. Based on an ongoing, interactive academic-biotech alliance with the lab of Dr. Lieping Chen at Yale School of Medicine, Normunity is targeting newly-discovered mechanisms of immune disruption in cancer based on proprietary discovery platforms that elucidate the complex interactions between human cancer and the immune system. The company is advancing an emerging pipeline of immune normalizers, including initial drug programs that target mechanisms that drive the exclusion of T-cells from immune-sensitive tumors and other mechanisms that are barriers to normal immune function in cancer. Normunity is located in Boston, Mass. and West Haven, Conn
Podimetrics is a virtual care management company dedicated to preventing costly and deadly diabetic amputations. We provide high-risk patients our FDA-cleared SmartMat™ through partnerships with payers and at-risk providers, including the Veterans Health Administration. After placing their feet on the mat for just 20 seconds a day, patients’ data are automatically sent to our care management team, which helps address any concerning findings. By combining cutting-edge technology with best-in-class care management, Podimetrics earns high engagement rates from patients, and allows clinicians to achieve unparalleled outcomes - keeping vulnerable patients healthy at home and saving limbs, lives, and money. Founded in 2011 by a physician and engineers from MIT and Harvard, Podimetrics is headquartered in Somerville, MA and backed by Norwich Ventures, Scientific Health Development, Polaris Partners, and Rock Health. For more information, go to www.podimetrics.com or follow us on Twitter @podimetrics.
Scorpion Therapeutics was founded to expand the reach of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0, a pipeline of targeted small-molecule drugs that overcome the limitations of existing treatments. Scorpion’s experienced leadership team is executing a fit-to-purpose model to efficiently unlock the next generation of precision oncology. For more information, visit scorpiontx.com.
ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. With a deep and global network, ArriVent seeks to access unique and best-in-class drug candidates at various development stages, including those coming from China and other emerging biotech hubs. Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with unmet medical need in a broad range of diseases, with an initial focus in oncology.
Motitus is a consulting firm specializing in biotechnology, pharmaceuticals, healthcare, life sciences, and health tech, working with ambitious leaders. We bridge the gap between thinking and implementation with extraordinary impact. We deliver mission projects that transform your business into state-of-the-art for the industry. The word Motitus carries a compelling narrative that resonates deeply within the realms of healthcare and innovation. The name itself, derived from the Latin word for "movement," encapsulates the essence of progress, dynamism, and transformation—qualities that are vital in the fast-evolving landscape of health and medicine. From its inception, Motitus aimed to be more than just a consultancy; it sought to be a catalyst for change. The brand's identity is built around the concept of movement, representing the fluidity and adaptability required in modern healthcare. Whether it’s helping a pharmaceutical company navigate regulatory hurdles or assisting a biotech startup in bringing its product to market, Motitus embodies the spirit of progress and agility.
iCarbonX is a technology company that is changing how people monitor and understand their health status and optimize their lives. We are building the platform and tools for digitizing, analyzing, and understanding life, and delivering intelligent products and applications—designed for every aspect and stage of life—to help everyone make smarter choices, every day. We’re inspired by every life on this planet, and by a commitment to apply intelligence not just to data, but to the ethical use of that data. Our mission is to bring people together to improve the human condition. We believe we must go beyond genetics to help people understand not just who they are, but how they are. We’re answering the “how” by combining biological and behavioral data with artificial intelligence in a network where people can learn from their own experience and from others like them, creating a global map of human health across cultures and continents that delivers new information and new choices, for life.
We offer solutions that bridge artificial intelligence (AI) and machine learning (ML), physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, and consumer goods companies, and regulatory agencies worldwide.
ProteinQure is a revenue-generating software platform for computational protein drug discovery. We combine molecular simulations, machine learning, and quantum computing to do the structure-based design of drugs. These physics-based methods make us less dependent on large data sets and that allows us to explore novel protein structures and interactions. We use our computational platform (as well as wetlab validation) to solve our partners drug design challenges and deliver new therapeutic candidates. We have a very diverse team of multi-disciplinary scientists and engineers. We are based in Toronto, Canada and are funded by top tier venture firms. If you are interested in building the next generation of computational biology tools we hope you will join us.
Work Your Passion. Live Your Purpose.